Fenwick Represents Cleerly in $192 Million Series C Financing

By: Matthew Rossiter, Ryan M. McRobert, Nikhil Sharma, Alexej Ladonnikov

Fenwick represented Cleerly, a company creating a new standard of care for heart disease, in its $192 million Series C financing. This new funding brings the total raised to $248 million, which includes its Series B financing in 2021.

The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company, with participation from Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.

Cleerly will use the new capital to expand its team as well as extend its commercial reach. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Matthew Rossiter and associates Ryan McRobert, Nikhil Sharma, Alexej Ladonnikov, and Danielle Coleman.

Login

Don’t have an account yet?

Register